Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Deferred Tax Liability (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Non-Current Deferred Tax Liability for 16 consecutive years, with $739733.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deferred Tax Liability fell 1.38% year-over-year to $739733.0, compared with a TTM value of $739733.0 through Sep 2025, down 1.38%, and an annual FY2024 reading of $731202.0, down 1.47% over the prior year.
  • Non-Current Deferred Tax Liability was $739733.0 for Q3 2025 at China Pharma Holdings, up from $734246.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $827978.0 in Q1 2022 and bottomed at $727417.0 in Q2 2023.
  • Average Non-Current Deferred Tax Liability over 5 years is $762469.4, with a median of $742114.0 recorded in 2023.
  • The sharpest move saw Non-Current Deferred Tax Liability grew 9.59% in 2021, then dropped 8.65% in 2022.
  • Year by year, Non-Current Deferred Tax Liability stood at $824407.0 in 2021, then decreased by 8.46% to $754698.0 in 2022, then dropped by 1.67% to $742114.0 in 2023, then decreased by 1.47% to $731202.0 in 2024, then grew by 1.17% to $739733.0 in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for CPHI at $739733.0 in Q3 2025, $734246.0 in Q2 2025, and $732241.0 in Q1 2025.